The Hannibal Clinic Research Center will launch a new clinical trial in Chronic Obstructive Pulmonary Disease (COPD) and Alpha One Deficiency on October 16, 2015.

The Hannibal Clinic Research Center will launch a new clinical trial in Chronic Obstructive Pulmonary Disease (COPD) and Alpha One Deficiency on October 16, 2015.

“This is a unique study opportunity because it will allow us to study inflammation where it matters most, at the level of the lung epithelium and the alveoli,” said Dr. Humam Farah, principal investigator. “The study will also look into the effect of the molecular size of the infusion medication on the lung parenchyma and the vascular system. The results will not only help patients with COPD and alpha one deficiency, but will advance our understanding of other disease processes like asthma and bronchiectasis. It will also help determine the safest optimal size of the infusion molecules that is safe for the cardiovascular system in other disease processes.”

The study will be conducted along with other leading institutions in the field in the United States and Canada.

Farah is a Pulmonary Critical Care and Sleep Medicine physician. He sees patients in his office in the Specialties department at the Hannibal Clinic. Farah is a Diplomate of the ABIM, holds Certification in Sleep Medicine, Critical Care Medicine, and Pulmonary Disease. He graduated from the Faculty of Medicine-University of Jordan. He completed his internship at Dr. Jamil Al-Tutanji Hospital Jordan in 1995.

Farah completed his residency in Internal Medicine at St. Louis University Hospital in 1999. Following his residency Dr. Farah completed a fellowship in Pulmonary/Critical and Sleep Medicine at the University of Illinois Chicago.